About ReNAgade Therapeutics
ReNAgade Therapeutics develops RNA medicines aimed at overcoming delivery challenges and creating a comprehensive therapeutic platform. The company has a proprietary toolkit that allows for precise disease correction by reprogramming cells to enhance gene expression, in partnership with Orna Therapeutics. Unlike traditional gene therapy, which replaces defective genes, ReNAgade's technology aims to permanently correct these genes and can insert larger genes or exons. Their goal is to provide curative therapies that address the genetic roots of diseases, serving clients in the medical and healthcare sectors.
Cambridge, MassachusettsHeadquarters
2021Year Founded
$291.8MTotal Funding
SERIES_ACompany Stage
Biotechnology, HealthcareIndustries
51-200Employees
Risks
Orna's acquisition may deprioritize ReNAgade's current projects or alter its business model.
Integration of GanNA Bio's technology may lead to corporate culture conflicts.
Reliance on joint ventures and licensing could expose ReNAgade to financial instability.
Differentiation
ReNAgade Therapeutics focuses on RNA therapeutics to treat diseases at their genetic root.
The company offers a unique all-RNA system for coding, editing, and gene insertion.
ReNAgade's proprietary toolkit enables precise disease correction on a large scale.
Upsides
Orna Therapeutics' acquisition may accelerate ReNAgade's RNA delivery system development.
GanNA Bio's extra-hepatic delivery technology enhances ReNAgade's RNA medicine effectiveness.
ReNAgade's non-viral, all-RNA gene editing offers safer therapeutic options.
Funding
Total raised$291.82 M
Latest valuation$1.50 B
StageSERIES_A
SERIES A
4/30/2023$300
$1.50 B